An observational study in Shared Decision Making, Cesarean Section and Anesthesia, Obstetrical, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of British Columbia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Shared decision-making (SDM) is the accepted ethical and legal standard for informed consent, but it is not known how it operates in anesthesia consent for cesarean delivery. Neuraxial anesthesia is recommended for most cesarean deliveries, and many anesthesiologists therefore present it as the only primary option, with general anesthesia (GA) available only as a rescue. Others present GA as a genuine alternative the patient can choose. This study will observe the existing variation in practice and will not change care. A trained observer will attend the pre-operative anesthesia consent encounter for women having an elective cesarean delivery at BC Women's Hospital and record which options were presented, using the observer-rated OPTION-5 instrument. Written research consent and a questionnaire follow on postpartum day 1 or 2, and include the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The primary aim is to compare patient-perceived SDM (SDM-Q-9) between consultations in which GA was offered as a genuine primary option and those in which it was not. This study hypothesizes that the SDM-Q-9 score will be higher when GA was offered as a primary option. Secondary aims are to describe observed SDM, decisional conflict, provider-level variation, and women's preference to be offered a choice in a future cesarean. The findings will inform a planned interventional trial of a standardized consent model.
Background. SDM, in which the clinician contributes evidence and the patient contributes values and preferences, is the ethical and increasingly the legal standard of consent (Hopp v Lepp; Reibl v Hughes; Montgomery v Lanarkshire). Major guidelines recommend neuraxial anesthesia for cesarean delivery because of the higher maternal risk of GA, and the SOAP Center of Excellence benchmark is a GA rate below 5%. Choice of technique is nevertheless preference-sensitive (being awake or asleep at the birth, partner presence, fear of needles or of awareness, prior trauma), and GA is routinely delivered when clinically required. Neuraxial block fails in about 5% of cesarean deliveries and intraoperative pain occurs in roughly 11-22%, a leading cause of maternal dissatisfaction and medicolegal action. The institutional consent discloses these risks. What varies between providers is choice: some present GA as a genuine primary option alongside neuraxial anesthesia, while others present neuraxial as the sole primary technique with GA only as rescue. A departmental poll found that 6 of 21 anesthesiologists (29%) report offering GA as a primary option. It is unknown whether offering GA as a genuine primary option affects women's perception of SDM.
Design. Single-centre, prospective, cross-sectional study at BC Women's Hospital, Vancouver. It combines (a) structured direct observation of the pre-operative anesthesia consent encounter and (b) a patient questionnaire on the 1st or 2nd postpartum day. No change is made to clinical care or to the consent process; existing variation in practice is the exposure. Because the anesthesiologist is assigned by the duty rota, women are quasi-randomly exposed to consent with or without a genuine primary choice.
Recruitment. A member of the circle of care (admitting nurse) asks the patient on the day of surgery whether they are willing to be approached. Only if they agree does a trained observer introduce the study and seek verbal consent to observation. Written informed consent is obtained on postpartum day 1 or 2 by a trained research assistant who is not the observer. The clinical anesthesia consent (routine care, observed) and the research consent (written, not observed) are separate processes. Providers receive an individual information sheet with an opt-out, and no per-case feedback is given. The specific exposure of interest is withheld from providers until study end; providers are not deceived about being observed. All anesthesiologists on the obstetric call roster, including the investigators, may be observed as consenting providers. In the calibration and reliability phase, the consenting provider may also be an anesthesia resident or fellow, who receives the same information sheet and opt-out.
Measures. Exposure: observer-classified offer of GA as a genuine primary option (yes/no). GA is classified as a genuine primary option when the provider presents it as an alternative the patient may choose for this delivery, alongside neuraxial anesthesia, whether or not the patient raised it first; GA mentioned only as a rescue or backup, or not mentioned, is classified as no choice offered. Observed SDM: OPTION-5. Perceived SDM: SDM-Q-9 (primary outcome). Decisional conflict: Decisional Conflict Scale, descriptive. Future-choice preference. Covariates: age, parity, prior cesarean, prior anesthesia experience, education, gestational age, technique received, consultation duration.
Observer calibration and reliability. Before recruitment, observers are calibrated against a reference rater (the Principal Investigator) on 10-15 real pre-operative consent consultations, completed together with the habituation run-in. An observer collects study data only after reaching ICC >= 0.70 for the OPTION-5 total and kappa >= 0.70 for the exposure classifier. Patients in this phase are not enrolled: they give verbal consent to the presence of two observers, and only the observers' anonymous ratings are retained, for reliability analysis only. During recruitment, enrolled encounters are double-rated periodically (about one to two per month); the trained observer's ratings enter the analysis and the second observer's ratings are used for reliability only.
Sample size and analysis. The primary analysis is a linear mixed-effects model with a random intercept for consenting provider, adjusted for covariates, reporting the adjusted mean difference with its 95% CI and the provider-level ICC. Assuming SD 12.4, alpha 0.05, a difference of 13.5 points, and ICC 0.10, 84 analyzable patients (4 per provider across 21 providers) give 97.7% power. Allowing about 20% attrition, the recruitment target is 105. A blinded biostatistician check of ICC, exposure split and SD after the first 105 patients will verify power; any increase in sample size will be submitted to the REB as an amendment. A pre-specified sensitivity analysis repeats the primary analysis excluding encounters in which an investigator was the consenting provider. Inter-rater reliability is reported as the ICC (two-way random effects, absolute agreement, single measures) for the OPTION-5 total and as Cohen's kappa for categorical elements, each with a 95% CI. Reporting follows STROBE.
Data. Data are held in the institutional BCCHR/PHSA-hosted REDCap instance, keyed by study ID, with the re-identification key stored separately. Records are retained for 5 years after study completion and publication.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Women aged 19 or older having an elective cesarean delivery at 37 weeks or later at BC Women's Hospital, with anesthesia consent obtained on the day of surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women whose observed pre-operative anesthesia consent presented general anesthesia as a genuine primary option the patient could choose, alongside neuraxial anesthesia, whether or not the patient raised it first. Classified per consultation by the trained observer.
Other: Observation of anesthesia consent encounter and postpartum questionnaire
Women whose observed pre-operative anesthesia consent presented neuraxial anesthesia as the sole primary technique, with general anesthesia available only as a rescue, or in which general anesthesia was not mentioned.
Other: Observation of anesthesia consent encounter and postpartum questionnaire
A trained non-treating observer attends and rates the routine pre-operative anesthesia consent encounter (OPTION-5). The patient completes a questionnaire on postpartum day 1 or 2 (SDM-Q-9, Decisional Conflict Scale). No change to clinical care.
Patient-perceived shared decision-making (SDM-Q-9 score)
Between-group difference in SDM-Q-9 total score (0-45), (higher = greater perceived involvement), between women whose consent included GA as a genuine primary option and those whose consent did not. Analysed with a linear mixed-effects model with a random intercept for consenting provider.
Time frame: Post-operative day 1 or 2
Proportion with adequate SDM-Q-9 score
Proportion of patients with an adequate 9-item Shared-Decision Making Score (SDM-Q-9,) score 0-45, transformed to a 0-100% scale, and using the top-box method to determine adequate (\>75%) vs inadequate (\<75%) scores, compared between exposure groups.
Time frame: Post-operative day 1 or 2
Observed shared decision-making (OPTION-5)
Observer-rated OPTION-5 score (0-20), with higher scores meaning higher observed levels of shared-decision making between provider and patient, overall and by exposure group, with concordance with the SDM-Q-9.
Time frame: Day of surgery, within 15 minutes of the consent encounter
Provider variability in offering choice
Proportion of consultations in which a genuine primary choice was offered; between-provider variation (ICC); whether offers were provider-initiated or prompted by patient questions; disclosure elements delivered.
Time frame: Day of surgery, at the consent encounter
Decisional conflict (Decisional Conflict Scale, 16-item)
DCS score by exposure group, reported descriptively (mean, 95% CI, proportion above 37.5, and floor proportion).
Time frame: Post-operative day 1 or 2
Preference for future choice
Proportion of women who would want to be offered a choice between neuraxial and general anesthesia in a future cesarean, overall and by exposure group and technique received.
Time frame: Post-operative day 1 or 2
Plan to share: No — There is currently no plan to share individual participant data (IPD). De-identified data may be made available if required by a journal as a condition of publication, subject to institutional, ethical, and privacy requirements.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →